1148 related articles for article (PubMed ID: 34446426)
1. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC
BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426
[TBL] [Abstract][Full Text] [Related]
2. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
Whiteley WN; Ip S; Cooper JA; Bolton T; Keene S; Walker V; Denholm R; Akbari A; Omigie E; Hollings S; Di Angelantonio E; Denaxas S; Wood A; Sterne JAC; Sudlow C;
PLoS Med; 2022 Feb; 19(2):e1003926. PubMed ID: 35192597
[TBL] [Abstract][Full Text] [Related]
3. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
[TBL] [Abstract][Full Text] [Related]
4. Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination.
Krzywicka K; van de Munckhof A; Sánchez van Kammen M; Heldner MR; Jood K; Lindgren E; Tatlisumak T; Putaala J; Kremer Hovinga JA; Middeldorp S; Levi MM; Cordonnier C; Arnold M; Zwinderman AH; Ferro JM; Coutinho JM; Aguiar de Sousa D
Neurology; 2022 Feb; 98(7):e759-e768. PubMed ID: 34921101
[TBL] [Abstract][Full Text] [Related]
5. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
Kerr S; Joy M; Torabi F; Bedston S; Akbari A; Agrawal U; Beggs J; Bradley D; Chuter A; Docherty AB; Ford D; Hobbs R; Katikireddi SV; Lowthian E; de Lusignan S; Lyons R; Marple J; McCowan C; McGagh D; McMenamin J; Moore E; Murray JK; Owen RK; Pan J; Ritchie L; Shah SA; Shi T; Stock S; Tsang RSM; Vasileiou E; Woolhouse M; Simpson CR; Robertson C; Sheikh A
PLoS Med; 2022 Feb; 19(2):e1003927. PubMed ID: 35192598
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
7. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.
Krzywicka K; Heldner MR; Sánchez van Kammen M; van Haaps T; Hiltunen S; Silvis SM; Levi M; Kremer Hovinga JA; Jood K; Lindgren E; Tatlisumak T; Putaala J; Aguiar de Sousa D; Middeldorp S; Arnold M; Coutinho JM; Ferro JM
Eur J Neurol; 2021 Nov; 28(11):3656-3662. PubMed ID: 34293217
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A
Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190
[TBL] [Abstract][Full Text] [Related]
9. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex.
Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236
[TBL] [Abstract][Full Text] [Related]
10. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.
Simpson CR; Shi T; Vasileiou E; Katikireddi SV; Kerr S; Moore E; McCowan C; Agrawal U; Shah SA; Ritchie LD; Murray J; Pan J; Bradley DT; Stock SJ; Wood R; Chuter A; Beggs J; Stagg HR; Joy M; Tsang RSM; de Lusignan S; Hobbs R; Lyons RA; Torabi F; Bedston S; O'Leary M; Akbari A; McMenamin J; Robertson C; Sheikh A
Nat Med; 2021 Jul; 27(7):1290-1297. PubMed ID: 34108714
[TBL] [Abstract][Full Text] [Related]
11. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
[TBL] [Abstract][Full Text] [Related]
12. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
Stowe J; Miller E; Andrews N; Whitaker HJ
PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
[TBL] [Abstract][Full Text] [Related]
13. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.
Li X; Burn E; Duarte-Salles T; Yin C; Reich C; Delmestri A; Verhamme K; Rijnbeek P; Suchard MA; Li K; Mosseveld M; John LH; Mayer MA; Ramirez-Anguita JM; Cohet C; Strauss V; Prieto-Alhambra D
BMJ; 2022 Oct; 379():e071594. PubMed ID: 36288813
[TBL] [Abstract][Full Text] [Related]
14. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD
Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.
Agrawal U; Katikireddi SV; McCowan C; Mulholland RH; Azcoaga-Lorenzo A; Amele S; Fagbamigbe AF; Vasileiou E; Grange Z; Shi T; Kerr S; Moore E; Murray JLK; Shah SA; Ritchie L; O'Reilly D; Stock SJ; Beggs J; Chuter A; Torabi F; Akbari A; Bedston S; McMenamin J; Wood R; Tang RSM; de Lusignan S; Hobbs FDR; Woolhouse M; Simpson CR; Robertson C; Sheikh A
Lancet Respir Med; 2021 Dec; 9(12):1439-1449. PubMed ID: 34599903
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.
Sánchez van Kammen M; Aguiar de Sousa D; Poli S; Cordonnier C; Heldner MR; van de Munckhof A; Krzywicka K; van Haaps T; Ciccone A; Middeldorp S; Levi MM; Kremer Hovinga JA; Silvis S; Hiltunen S; Mansour M; Arauz A; Barboza MA; Field TS; Tsivgoulis G; Nagel S; Lindgren E; Tatlisumak T; Jood K; Putaala J; Ferro JM; Arnold M; Coutinho JM; ; Sharma AR; Elkady A; Negro A; Günther A; Gutschalk A; Schönenberger S; Buture A; Murphy S; Paiva Nunes A; Tiede A; Puthuppallil Philip A; Mengel A; Medina A; Hellström Vogel Å; Tawa A; Aujayeb A; Casolla B; Buck B; Zanferrari C; Garcia-Esperon C; Vayne C; Legault C; Pfrepper C; Tracol C; Soriano C; Guisado-Alonso D; Bougon D; Zimatore DS; Michalski D; Blacquiere D; Johansson E; Cuadrado-Godia E; De Maistre E; Carrera E; Vuillier F; Bonneville F; Giammello F; Bode FJ; Zimmerman J; d'Onofrio F; Grillo F; Cotton F; Caparros F; Puy L; Maier F; Gulli G; Frisullo G; Polkinghorne G; Franchineau G; Cangür H; Katzberg H; Sibon I; Baharoglu I; Brar J; Payen JF; Burrow J; Fernandes J; Schouten J; Althaus K; Garambois K; Derex L; Humbertjean L; Lebrato Hernandez L; Kellermair L; Morin Martin M; Petruzzellis M; Cotelli M; Dubois MC; Carvalho M; Wittstock M; Miranda M; Skjelland M; Bandettini di Poggio M; Scholz MJ; Raposo N; Kahnis R; Kruyt N; Huet O; Sharma P; Candelaresi P; Reiner P; Vieira R; Acampora R; Kern R; Leker R; Coutts S; Bal S; Sharma SS; Susen S; Cox T; Geeraerts T; Gattringer T; Bartsch T; Kleinig TJ; Dizonno V; Arslan Y
JAMA Neurol; 2021 Nov; 78(11):1314-1323. PubMed ID: 34581763
[TBL] [Abstract][Full Text] [Related]
18. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.
Horne EMF; Hulme WJ; Keogh RH; Palmer TM; Williamson EJ; Parker EPK; Green A; Walker V; Walker AJ; Curtis H; Fisher L; MacKenna B; Croker R; Hopcroft L; Park RY; Massey J; Morley J; Mehrkar A; Bacon S; Evans D; Inglesby P; Morton CE; Hickman G; Davy S; Ward T; Dillingham I; Goldacre B; Hernán MA; Sterne JAC
BMJ; 2022 Jul; 378():e071249. PubMed ID: 35858698
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
[TBL] [Abstract][Full Text] [Related]
20. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
